entertainment -WSS

entertainment

author：Wikipedia 2025-09-29 22:54:08 - browse：67831

STAT's Megan Molteni speaks with Feng Zhang in New York on March 21, 2024 — Scientist Feng Zhang, right, is interviewed by reporter Megan Molteni at STAT's Breakthrough Summit East. STAT

When the first biotech companies emerged to capitalize on the revolutionary genome-editing technology CRISPR, Editas Medicine seemed like the pacesetter. It locked up some of the crucial IP, and had behind it the pioneering scientist Feng Zhang of the Broad Institute as one of its founders.

But now, a decade later, Editas is seen as lagging behind its peers. CRISPR Therapeutics, in partnership with Vertex Pharmaceuticals, won the race to get the first CRISPR-based medicine across the finish line. Intellia Therapeutics was the first to show that CRISPR editing could be performed inside the body. Editas, meanwhile, has seen a revolving door among its executives.

So what happened?

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： How Long Island became the ‘eugenics capital of the world’

focus

WSS

Apellis safety probe of eye disease drug centers on injection needle

AstraZeneca challenges Medicare drug negotiation program

Military medical care influenced by rank and race, new study finds

FDA panel gives mixed vote on blood pressure devices

How to make Best Hospitals ratings actually useful for patients

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

hotspot

entertainment

hotspot

In Memoriam: Notable people who died in 2023

Military medical care influenced by rank and race, new study finds

Trump demands the U.S. pay no more for drugs than other countries … again

Readout LOUD podcast: Live from STAT Breakthrough Summit West

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Study finds new variant for Parkinson’s in African populations

United colonoscopy coverage change 'may cost lives,' doctors say

Criminal prosecution for violating HIPAA: an emerging threat

Peter Hotez and the public health issue of online harassment

Venture capitalist Bob Kocher on the state of digital health

leisure time

Glen Campbell's doctor discusses his public struggle with Alzheimer's

How a symptom of dementia informs our understanding of creativity

NVIDIA and Google execs on the future of AI and drug discovery

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Data integrity in scientific journals requires "effort" by publishers, institutions

Readers respond to H5N1 and livestock movements, and more

explore

Wikipedia

focus

hotspot